Pharmaceuticals

Well Begun AND Half Done! - SIRONA Randomized Trial Achieves fifty percent enrollment

JENA, Germany, Feb. 10, 2022 /PRNewswire/ -- Concept Medical Inc.,  focused on vascular intervention drug delivery devices, releases the second status update of SIRONA RCT (Head-to-Head Comparison ofSIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in ...

2022-02-10 08:21 3865

X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets

LONDON and HYDERABAD, India, Feb. 9, 2022 /PRNewswire/ -- A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets...

2022-02-09 22:00 4612

Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microspheres in China from the National Medical Products Administration

SIR-Spheres® Y-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the NMPA in 2022 WOBURN, Mass., Feb. 9, 2022 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today with its shareholder, Grand Pharmaceut...

2022-02-09 21:30 2294

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...

2022-02-09 17:10 2837

CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia

* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation * Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chines...

2022-02-09 11:53 5612

Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India

This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, ...

2022-02-09 10:00 11286

Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year

EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service....

2022-02-08 22:30 4053

WuXi Biologics Statement

SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...

2022-02-08 11:08 4267

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron * By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in monkeys were 3.2-fold and 2.3-fold of Molnupiravir, respecti...

2022-02-07 19:00 4595

The one-component Sputnik Light vaccine has been authorized in India; over 2.5 billion people live in countries that approved Sputnik Light as a standalone vaccine and a universal booster

Sputnik Light will be an important part of India's vaccination program and the fight against mutations of COVID, including Omicron. Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people. MOSCOW, Feb. 7, 2022  /PRNewswire/ --  The Russian Dir...

2022-02-07 08:18 5425

Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Feb. 7, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia...

2022-02-07 08:00 5586

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors * The first U.S. patient is expected to be dosed in the first half of 2022 * ASC61 shows significant antitumor efficacy as a single agent i...

2022-02-06 18:30 5496

Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms

Cytognos divestment is a first strategic step aimed at positioning Vitro as a new worldwide diagnostic player in their key market segments SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio ) a privately held company headquartered in Seville, Spain, ann...

2022-02-04 17:23 5223

Nanoform signs GMP manufacturing program with TargTex following formulation success

HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...

2022-02-04 15:54 3543

Mentice publishes the company's year-end report for the period January-December 2021

STOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) * Order intake amounted to 73.7 (73.1) MSEK. * Net sales amounted to 67.7 (45.9) MSEK. * Operating income for the period before depreciation...

2022-02-03 15:37 2630

CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma

LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...

2022-02-02 11:00 4782

World's most trusted source for chemistry information, CAS, launches major biology expansion

CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...

2022-02-02 10:42 3900

Cytiva fuels biotech development in Australia and New Zealand

* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...

2022-02-01 07:00 3754

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com ), a Swiss biopharmaceutical company andAspen, a South African headquartered multinational pharmaceutical company announced today their partnership to  launch Tr...

2022-02-01 06:00 3819

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...

2022-02-01 05:30 3049
1 ... 166167168169170171172 ... 184

Week's Top Stories